Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study

Colombo et al. • 2023 • Journal of Clinical Oncology

Read more

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

Simeoli et al. • 2023 • ENDO 2023

Read more

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Frias et al. • 2023 • ENDO 2023

Read more

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference

Read more

https://corcept.com/wp-content/uploads/2023/07/ECE2023-1.pdf

Simeoli et al. • 2023 • European Congress of Endocrinology

Read more

An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

Badiu et al. • 2023 • European Congress of Endocrinology

Read more

https://corcept.com/wp-content/uploads/2023/05/AACE2023-2.pdf

Donegan et al. • 2023 • AACE 2023

Read more

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Frias et al. • 2023 • AACE 2023

Read more

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube